International Myeloma Society 3rd Annual Workshop on Genomics 2025

The 3rd Annual Genomics Meeting: Genomics and Translational Medicine in Myeloma is a premier, specialized scientific conference organized by the International Myeloma Society (IMS). This event is dedicated to exploring the rapidly evolving genomic landscape of multiple myeloma and related plasma cell dyscrasias. The program focuses on bridging the gap between basic scientific discovery and clinical application, highlighting cutting-edge research in clonal evolution, tumor microenvironment interactions, single-cell technologies, and personalized medicine. By bringing together global experts, the meeting aims to accelerate the translation of genomic data into novel, targeted therapeutic strategies to improve patient outcomes.
Learning Objectives
Upon completion of this educational program, participants will be able to:

Understand the complex genomic architecture, mutational mutational signatures, and clonal evolution of multiple myeloma from precursor states (MGUS/Smoldering Myeloma) to relapsed/refractory disease.

Evaluate the clinical utility and implementation of advanced genomic technologies, including next-generation sequencing (NGS), single-cell sequencing, and spatial transcriptomics.

Interpret the role of the bone marrow microenvironment and immune evasion mechanisms in myeloma progression and response to immunotherapy.

Apply molecular and genetic profiling to risk stratification, minimal residual disease (MRD) monitoring via liquid biopsies, and the selection of precision medicine therapeutics.

Target Audience

This meeting is designed for hematologists, medical oncologists, basic and translational scientists, clinical researchers, molecular pathologists, and fellows in training who are dedicated to the study, diagnosis, and management of multiple myeloma and related plasma cell disorders.
Best for hematologists, medical oncologists, molecular pathologists, geneticists, and immunologists.

Topics:

Session 1 – Current Definition and Management of Precursor Conditions
Session 2 – Precursor Disease Genomics and Microenvironment
Session 3 – The Future of Precursor Disease – Balancing Treatment and Innovation
Session 4 – Deciphering Single Cells in MM
Session 5 – Genomics in MM and Other Plasma Cell Dyscrasias
Session 6 – Novel Targets in Plasma Cell Dyscrasias
Session 7 – MM and Other Plasma Cell Disorders
Session 8 – Proteomics and Methylation